返回 
加入收藏
海曲泊帕联合重组人血小板生成素治疗原发免疫性血小板减少症的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 海曲泊帕联合重组人血小板生成素治疗原发免疫性血小板减少症的临床观察 |
| TITLE： | Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia |
| 摘要： | 目的 探讨海曲泊帕联合重组人血小板生成素（rhTPO）治疗原发免疫性血小板减少症（ITP）在真实世界中的临床疗效和安全性。方法回顾性选取2021年1月至2022年12月蚌埠医学院第二附属医院诊断为ITP的患者，将其中使用海曲泊帕联合rhTPO的98例患者设为观察组，使用rhTPO的157例患者设为对照组。观察并比较2组患者治疗前后的血小板计数、临床疗效、出血情况、血小板输注率和不良反应发生情况。结果从治疗第8天[观察组为（61.04±13.46）×109L－1，对照组为（52.11±12.06）×109L－1]开始，2组患者的血小板计数差异有统计学意义（P＜0.05），且2组患者血小板计数的峰值和稳定值差异均有统计学意义（P＜0.05）。观察组与对照组患者的总有效率分别为79.59%和66.88%，累积达终点率分别为81.32%与68.68%，中位有效时间分别为8d和10d，差异均有统计学意义（P＜0.05）。治疗期间观察组与对照组患者的出血率分别为3.06%和8.28%（P＜0.05），出血等级均为1级或2级；血小板输注率分别为31.63%和40.76%，差异有统计学意义（P＜0.05）。2组患者不良反应发生率分别为11.22%和9.55%，差异无统计学意义（P＞0.05），且均无中重度不良反应记录。结论海曲泊帕联合rhTPO能显著提高ITP患者的血小板水平和有效率，降低出血率和血小板输注率，并具有良好的安全性。 |
| ABSTRACT： | OBJECTIVE To investigate the clinical efficacy and safety of herombopag combined with recombinant human thrombopoietin （rhTPO） in the treatment of primary immune thrombocytopenia （ITP） in the real world. METHODS A retrospective study was conducted on the patients diagnosed with ITP in the Second Affiliated Hospital of Bengbu Medical College from January 2021 to December 2022. Among them， 98 patients who were treated with a combination of herombopag and rhTPO were included in the observation group， and 157 patients who were treated with rhTPO alone were included in the control group. The changes in platelet count， clinical efficacy， bleeding， platelet transfusion rate and adverse drug reactions before and after treatment were observed and compared between the two groups. RESULTS Since the 8th day of treatment， there was a statistically significant difference in platelet count between the two groups （[ 61.04±13.46）×109 L－1 in observation group， （52.11±12.06）× 109 L－1 in control group] （P＜0.05）， and there also was a statistically significant difference in the peak and stable values of platelet count between the two groups （P＜0.05）. The total effective rates of the observation group and the control group were 79.59% and 66.88%， with cumulative response rates of 81.32% and 68.68%， and median response durations of 8 days and 10 days， respectively； these differences were statistically significant （P＜0.05）. During the treatment period， the bleeding rates of the observation group and control group were 3.06% and 8.28% （P＜0.05）， bleeding events were categorized as grade 1 or 2， and platelet transfusion rates were 31.63% and 40.76%； the differences in bleeding rates and platelet transfusion rates between the two groups was statistically significant （P＜0.05）. The incidences of adverse drug reactions in the two groups were 11.22% and 9.55%， respectively， with no statistically significant difference （P＞0.05）， and no moderate to severe adverse drug reaction was found. CONCLUSIONS The combination of herombopag and rhTPO can significantly increase platelet levels and response rate， and reduce bleeding rate and platelet transfusion rate in ITP patients， with good safety. |
| 期刊： | 2023年第34卷第23期 |
| 作者： | 郭星；赵丹；左金曼 |
| AUTHORS： | GUO Xing，ZHAO Dan，ZUO Jinman |
| 关键字： | 海曲泊帕；重组人血小板生成素；原发免疫性血小板减少症；疗效；安全性 |
| KEYWORDS： | herombopag； recombinant human thrombopoietin； primary immune thrombocytopenia； clinical efficacy； safety |
| 阅读数： | 196 次 |
| 本月下载数： | 9 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
